Literature DB >> 20842283

Hormonal contraceptive options for women with headache: a review of the evidence.

Andrea G Edlow1, Deborah Bartz.   

Abstract

Migraine affects as many as 37% of reproductive-age women in the United States. Hormonal contraception is the most frequently used form of birth control during the reproductive years, and given the significant proportion of reproductive-age women affected by migraine, there are several clinical considerations that arise when considering hormonal contraceptives in this population. In this review, key differences among headache, migraine, and migraine with aura, as well as strict diagnostic criteria, are described. The recommendations of the World Health Organization and the American College of Obstetricians and Gynecologists regarding hormonal contraception initiation and continuation in women with these diagnoses are emphasized. Finally, information about the effect of hormonal fluctuations on headache is provided with recommendations regarding contraception counseling in patients who experience headache while taking hormonal contraception.

Entities:  

Keywords:  Estrogen; Hormonal contraceptives; Migraine with aura; Migraine without aura; Progesterone; Stroke

Year:  2010        PMID: 20842283      PMCID: PMC2938905     

Source DB:  PubMed          Journal:  Rev Obstet Gynecol        ISSN: 1941-2797


  70 in total

Review 1.  Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review.

Authors:  Elizabeth W Loder; Dawn C Buse; Joan R Golub
Journal:  Am J Obstet Gynecol       Date:  2005-09       Impact factor: 8.661

2.  ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions.

Authors: 
Journal:  Obstet Gynecol       Date:  2006-06       Impact factor: 7.661

3.  Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study.

Authors:  E A MacGregor; A Frith; J Ellis; L Aspinall; A Hackshaw
Journal:  Neurology       Date:  2006-12-26       Impact factor: 9.910

4.  Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo.

Authors:  N S Al-Waili
Journal:  Eur J Med Res       Date:  2000-04-19       Impact factor: 2.175

5.  A nosographic analysis of the migraine aura in a general population.

Authors:  M B Russell; J Olesen
Journal:  Brain       Date:  1996-04       Impact factor: 13.501

6.  Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study.

Authors:  O Lidegaard
Journal:  BMJ       Date:  1993-04-10

Review 7.  Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials.

Authors:  A Edelman; M F Gallo; M D Nichols; J T Jensen; K F Schulz; D A Grimes
Journal:  Hum Reprod       Date:  2006-03       Impact factor: 6.918

8.  Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan.

Authors:  M P Solbach; R S Waymer
Journal:  Obstet Gynecol       Date:  1993-11       Impact factor: 7.661

Review 9.  Advances in the basic and clinical science of migraine.

Authors:  Andrew Charles
Journal:  Ann Neurol       Date:  2009-05       Impact factor: 10.422

10.  Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials.

Authors:  Lisa K Mannix; Vincent T Martin; Roger K Cady; Merle L Diamond; Shelly E Lener; Jonathan D White; Frederick J Derosier; Susan A McDonald
Journal:  Obstet Gynecol       Date:  2009-07       Impact factor: 7.661

View more
  12 in total

Review 1.  Hormonal contraception and migraine: clinical considerations.

Authors:  Stephanie S Faubion; Petra M Casey; Lynne T Shuster
Journal:  Curr Pain Headache Rep       Date:  2012-10

2.  Postoperative pain, nausea and vomiting among pre- and postmenopausal women undergoing cystocele and rectocele repair surgery.

Authors:  Sepideh Vahabi; Abolfazl Abaszadeh; Fatemeh Yari; Nazanin Yousefi
Journal:  Korean J Anesthesiol       Date:  2015-11-25

3.  Migraine diagnosis and treatment: A knowledge and needs assessment of women's healthcare providers.

Authors:  Allison M S Verhaak; Anne Williamson; Amy Johnson; Andrea Murphy; Matthew Saidel; Abigail L Chua; Mia Minen; Brian M Grosberg
Journal:  Headache       Date:  2020-12-30       Impact factor: 5.887

Review 4.  Headache for ophthalmologists: current advances in headache understanding and management.

Authors:  Susan P Mollan; Jasvir S Virdee; Edward J Bilton; Mark Thaller; Anita Krishan; Alexandra J Sinclair
Journal:  Eye (Lond)       Date:  2021-02-12       Impact factor: 4.456

Review 5.  Symptomatology of irritable bowel syndrome and inflammatory bowel disease during the menstrual cycle.

Authors:  Shishira Bharadwaj; Matthew D Barber; Lesley A Graff; Bo Shen
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-03-18

6.  Does oral contraceptive pill increase the risk of abnormal Pap smear?

Authors:  Fariba Binesh; Ali Akhavan; Azar Pirdehghan; Mahnoosh Davoodi
Journal:  Iran J Reprod Med       Date:  2013-09

Review 7.  Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: a review of the literature.

Authors:  Rossella E Nappi; Marco Serrani; Jeffrey T Jensen
Journal:  Int J Womens Health       Date:  2014-08-02

Review 8.  Oral contraception following abortion: A systematic review and meta-analysis.

Authors:  Yan Che; Xiaoting Liu; Bin Zhang; Linan Cheng
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

9.  Glutamate-system defects behind psychiatric manifestations in a familial hemiplegic migraine type 2 disease-mutation mouse model.

Authors:  Pernille Bøttger; Simon Glerup; Bodil Gesslein; Nina B Illarionova; Toke J Isaksen; Anders Heuck; Bettina H Clausen; Ernst-Martin Füchtbauer; Jan B Gramsbergen; Eli Gunnarson; Anita Aperia; Martin Lauritzen; Kate L Lambertsen; Poul Nissen; Karin Lykke-Hartmann
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

10.  Oral contraceptive misuse as a risk factor for cerebral venous and sinus thrombosis.

Authors:  Mohammad Saadatnia; Neda Naghavi; Farzad Fatehi; Mohammad Zare; Marzieh Tajmirriahi
Journal:  J Res Med Sci       Date:  2012-04       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.